Corrigendum to "Potential use of an estrogen-glucocorticoid receptor chimera as a drug screen for tissue selective estrogenic activity" [Bone 44 (2009) 102-112] (DOI:10.1016/j.bone.2008.09.016);Potential use of an estrogen-glucocorticoid receptor chimera as a drug screen for tissue selective estrogenic activity

Bone

Volumn 44, Issue 1, 2009, Pages 102-112

  Maru, Benit S ^a   Tobias, Jonathan H ^a   Rivers, Caroline ^a   Caunt, Christopher J ^a   Norman, Michael R ^a   McArdle, Craig A ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Estradiol; Estrogen receptor alpha; Osteoblasts; Reporter assay; SERMs

Indexed keywords

4 HYDROXYTAMOXIFEN; ANTIESTROGEN; COMPLEMENTARY DNA; DEXAMETHASONE; DIENESTROL; EPIDERMAL GROWTH FACTOR; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; GLUCOCORTICOID RECEPTOR; GREEN FLUORESCENT PROTEIN; HEXESTROL; PHORBOL DIBUTYRATE; PLASMID DNA; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; UNCLASSIFIED DRUG; ZK 164015;

ARTICLE; CELL STRAIN MCF 7; CHIMERA; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG SELECTIVITY; ESTROGEN ACTIVITY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; OSTEOBLAST; OSTEOSARCOMA CELL; TISSUE SPECIFICITY;

EID: 57449091869     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2009.02.005     Document Type: Erratum

References (32)

1. Perry M.J., Gujral S., Whitworth T., and Tobias J.H. Tamoxifen stimulates cancellous bone formation in long bones of female mice. Endocrinology 146 (2005) 1060-1065
2. Qu Q., Harkonen P.L., and Vaananen H.K. Comparative effects of estrogen and antiestrogens on differentiation of osteoblasts in mouse bone marrow culture. J. Cell. Biochem. 73 4 (1999) 500-507
3. Taranta A., Brama M., Teti A., De luca V., Scandurra R., Spera G., et al. The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro. Bone 30 2 (2002) 368-376
4. Tobias J.H., and Compston J.E. Does estrogen stimulate osteoblast function in postmenopausal women?. Bone 24 (1999) 121-124
5. Ong D.B., Colley S.M., Norman M.R., Kitazawa S., and Tobias J.H. Transcriptional regulation of a BMP-6 reporter by estrogen receptor alpha. J. Bone Miner. Res. 19 (2004) 447-454
6. Tou L., Quibria N., and Alexander J.M. Regulation of human cbfa1 gene transcription in osteoblasts by selective estrogen receptor modulators (SERMs). Mol. Cell. Endocrinol 183 (2001) 71-79
7. van den Wijngaard A., Mulder W.R., Dijkema R., Boersma C.J., Mosselman S., van Zoelen E.J., et al. Antiestrogens specifically up-regulate bone morphogenetic protein-4 promoter activity in human osteoblastic cells. Mol. Endocrinol. 14 5 (2000) 623-633
8. Yang N.N., Venugopalan M., Hardikar S., and Glasebrook A. Identification of an estrogen response element activated by metabolites of 17beta-estradiol and raloxifene. Science 273 5279 (1996) 1222-1225
9. Gallagher A., Chambers T.J., and Tobias J.H. The estrogen antagonist ICI 182,780 reduces cancellous bone volume in female rats. Endocrinology 133 (1993) 2787-2791
10. Paige L.A., Christensen D.J., Gron H., Norris J.D., Gottlin E.B., Padilla K.M., et al. Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 3999-4004
11. Smith C.L., and O'Malley B.W. Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr. Rev. 25 1 (2004) 45-71
12. Maruvada P., Baumann C.T., Hager G.L., and Yen P.M. Dynamic shuttling and intranuclear mobility of nuclear hormone receptors. J. Biol. Chem. 278 14 (2003) 12425-12432
13. Martinez E.D., Rayasam G.V., Dull A.B., Walker D.A., and Hager G.L. An estrogen receptor chimera senses ligands by nuclear translocation. J. Steroid Biochem. Mol. Biol. 97 4 (2005) 307-321
14. Stenoien D.L., Patel K., Mancini M.G., Dutertre M., Smith C.L., O'Malley B.W., et al. FRAP reveals that mobility of oestrogen receptor-alpha is ligand- and proteasome-dependent. Nat. Cell Biol. 3 1 (2001) 15-23
15. Reid G., Hubner M.R., Metivier R., Brand H., Denger S., Manu D., et al. Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. Mol. Cell 11 3 (2003) 695-707
16. Driggers P.H., and Segars J.H. Estrogen action and cytoplasmic signaling pathways. Part II: the role of growth factors and phosphorylation in estrogen signaling. Trends Endocrinol. Metab. 13 10 (2002) 422-427
17. Katzenellenbogen B.S., Choi I., Delage-Mourroux R., Ediger T.R., Martini P.G., Montano M., et al. Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology. J. Steroid Biochem. Mol. Biol. 74 5 (2000) 279-285
18. Likhite V.S., Stossi F., Kim K., Katzenellenbogen B.S., and Katzenellenbogen J.A. Kinase-specific phosphorylation of the estrogen receptor changes receptor interactions with ligand, deoxyribonucleic acid, and coregulators associated with alterations in estrogen and tamoxifen activity. Mol. Endocrinol. 20 12 (2006) 3120-3132
19. Michalides R., Griekspoor A., Balkenende A., Verwoerd D., Janssen L., Jalink K., et al. Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer. Cancer Cell 5 6 (2004) 597-605
20. Kousteni S., Almeida M., Han L., Bellido T., Jilka R.L., and Manolagas S.C. Induction of osteoblast differentiation by selective activation of kinase-mediated actions of the estrogen receptor. Mol. Cell. Biol. 27 4 (2007) 1516-1530
21. Pratt W.B., Morishima Y., Murphy M., and Harrell M. Chaperoning of glucocorticoid receptors. Handb. Exp. Pharmacol. 172 (2006) 111-138
22. Elbi C., Walker D.A., Romero G., Sullivan W.P., Toft D.O., Hager G.L., et al. Molecular chaperones function as steroid receptor nuclear mobility factors. Proc. Natl. Acad. Sci. U. S. A. 101 9 (2004) 2876-2881
23. Ogawa S., Oishi H., Mezaki Y., Kouzu-Fujita M., Matsuyama R., Nakagomi M., et al. Repressive domain of unliganded human estrogen receptor alpha associates with Hsc70. Genes Cells 10 12 (2005) 1095-1102
24. Nakamura T., Imai Y., Matsumoto T., Sato S., Takeuchi K., Igarashi K., et al. Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell 130 5 (2007) 811-823
25. Smith E.C., Boyd J., Frank G.R., Takahashi H., Cohen R.M., Specker B., et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N. Engl. J. Med. 331 (1994) 1056-1061
26. McDougall K.E., Perry M.J., Gibson R., Bright J., Colley S., Hodgin J.B., et al. Estrogen-induced osteogenesis in intact female mice lacking ERbeta. Am. J. Physiol. 283 (2002) E817-E823
27. McDougall K.E., Perry M.J., Gibson R.L., Colley S.M., Korach K.S., and Tobias J.H. Estrogen receptor-alpha dependency of estrogen's stimulatory action on cancellous bone formation in male mice. Endocrinology 144 5 (2003) 1994-1999
28. Arts J., Kuiper G.G.J.M., Janssen J.M.M.F., Gustafsson J.A., Lowik C.W.G.M., Pols H.A.P., et al. Differential expression of estrogen receptors alpha and beta mRNA during differentiation of human osteoblast SV-HFO cells. Endocrinology 138 (1997) 5067-5070
29. Bord S., Horner A., Beavan S., and Compston J. Estrogen receptor alpha and beta are differentially expressed in developing human bone. J. Clin. Endocrinol. Metab. 86 (2001) 2309-2314
30. Onoe Y., Miyaura C., Ohta H., Nozawa S., and Suda T. Expression of estrogen receptor beta in rat bone. Endocrinology 138 (1997) 4509-4512
31. Monroe DG, Secreto FJ, Subramaniam M, Getz BJ, Khosla S, Spelsberg TC. Estrogen receptor alpha and beta heterodimers exert unique effects on estrogen- and tamoxifen-dependent gene expression in human U2OS osteosarcoma cells 2005.
32. Prossnitz E.R., Arterburn J.B., and Sklar L.A. GPR30: a G protein-coupled receptor for estrogen. Mol. Cell. Endocrinol. 265-266 (2007) 138-142